Safety Profile

Semaglutide Side Effects & Safety

Q: Are semaglutide side effects permanent?

Most common side effects resolve within 4-8 weeks of starting or titrating. GI symptoms typically improve as the body adapts. Serious adverse events are rare.

Q: Can semaglutide cause thyroid cancer?

Rodent studies showed C-cell tumor development. Human epidemiological data has not confirmed this risk. The FDA maintains a black-box warning out of caution.

Semaglutide has one of the most extensively documented safety profiles in peptide medicine, with over a decade of clinical use. GI effects predominate and are usually transient.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Black Box Warning

Risk of thyroid C-cell tumors observed in rodent studies. Human relevance is unknown. Contraindicated in patients with personal or family history of MTC or MEN 2.

Side effects by severity

Serious1 effect

Medullary thyroid carcinoma (MTC)

Observed in rodents; human relevance uncertain. Black box warning.

Common5 effects

Nausea

20-44%

Most common side effect. Typically peaks in first 4-8 weeks and resolves with continued use.

Diarrhea

30%

Dose-related; usually mild to moderate.

Vomiting

9-24%

More common at higher doses and during titration.

Constipation

11-24%

Due to slowed gastric and intestinal transit.

Abdominal pain

12-20%

Usually mild; persistent severe pain warrants evaluation.

Uncommon4 effects

Injection site reactions

<10%

Redness, itching, mild swelling at injection site.

Fatigue

Reported in early weeks of therapy.

Headache

Typically transient.

Gallbladder disease

~2%

Including cholelithiasis and cholecystitis. Risk increases with rapid weight loss.

Rare4 effects

Acute pancreatitis

<1%

Presents with severe persistent abdominal pain radiating to back. Discontinue if suspected.

Diabetic retinopathy complications

In patients with pre-existing retinopathy. Monitor in T2D patients.

Acute kidney injury

Usually related to volume depletion from severe GI symptoms.

Severe hypoglycemia

Uncommon as monotherapy; increased risk with insulin or sulfonylureas.

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Prior hypersensitivity to semaglutide or any component

Drug interactions

Insulin and sulfonylureas — increased hypoglycemia risk; may require dose reduction
Oral medications — delayed gastric emptying may alter absorption of concurrently administered drugs
Warfarin — monitor INR more frequently when starting or adjusting

Special populations

Not recommended in pregnancy (weight-loss indication) due to potential fetal harm. Limited pediatric data under age 12; approved down to age 12 for obesity. No specific dose adjustments for elderly.

Safety summary

Semaglutide has a favorable overall safety profile validated by multiple cardiovascular outcome trials (SUSTAIN-6, SELECT) and large real-world cohorts. Most adverse events are GI and self-limiting. Serious events are rare but include pancreatitis and gallbladder disease.

Frequently asked

Are semaglutide side effects permanent?